1. HBW Insight
  2. >>Beauty
  3. >>Business
  4. >>Earnings

Rejuvenated A Year Into Saunders’ Return To Helm, B+L Refreshing Blink, Lumify Lines

 
• By Malcolm Spicer

Brimonidine tartrate eye drops remain key sales driver among Canadian firm’s consumer health lines with 12% growth in the latest quarter. B+L expects pending launch of preservative-free line extension to sustain Lumify as a driver as generics of original formulation are approved.

• Source: Shutterstock

Any honeymoon expected for Brent Saunders at Bausch + Lomb, Corporation may or may not be over after a year at the helm, but the special period known as market exclusivity the firm’s Lumify OTC switch eye drops enjoyed in the US could be passing with the first generic copy approved.

The brimonidine tartrate 0

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on HBW Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Earnings

Shiseido’s Key Priorities: Recover Drunk Elephant, Accelerate NARS Amid US Prestige Slowdown

 
• By Eileen Francis

Shiseido’s Drunk Elephant premium skin care range – acquired in 2019 – and its NARS brand dragged sales in the Americas region down almost 20% in the first quarter, the firm reported in a 12 May earnings presentation.

IFF Offsets Tariffs’ Impact, But Discretionary Product Ingredients Face Risk

 
• By Eileen Francis

New York-based International Flavors & Fragrance, Inc. has shifted procurement to alternative supply sources and is balancing production across its global network in response to US tariffs, though company executives say ingredients for discretionary products face risk.

Coty Lowers FY25 Forecast On Tariff Uncertainty, Inventory Reductions, But Expects Sunnier Days In FY26

 
• By Eileen Francis

Coty lowers its revenue and profit outlook for FY25, though it believes FY26 will be a better year thanks to a return of ‘blockbuster’ product launches, market expansion and mitigation strategies for current economic uncertainties.

Estee Lauder Lowers FY 2025 Outlook, Expects Positive Results FY 2026 On ‘Beauty Reimagined’

 
• By Eileen Francis

The Estee Lauder Companies reported a 10% drop in reported sales during its fiscal third quarter presentation on a 28% decline in travel retail organic sales. The firm, which lowered its FY 2025 sales expectations, says it expects positive growth in FY 2026.

More from Business

Shiseido’s Key Priorities: Recover Drunk Elephant, Accelerate NARS Amid US Prestige Slowdown

 
• By Eileen Francis

Shiseido’s Drunk Elephant premium skin care range – acquired in 2019 – and its NARS brand dragged sales in the Americas region down almost 20% in the first quarter, the firm reported in a 12 May earnings presentation.

IFF Offsets Tariffs’ Impact, But Discretionary Product Ingredients Face Risk

 
• By Eileen Francis

New York-based International Flavors & Fragrance, Inc. has shifted procurement to alternative supply sources and is balancing production across its global network in response to US tariffs, though company executives say ingredients for discretionary products face risk.

Coty Lowers FY25 Forecast On Tariff Uncertainty, Inventory Reductions, But Expects Sunnier Days In FY26

 
• By Eileen Francis

Coty lowers its revenue and profit outlook for FY25, though it believes FY26 will be a better year thanks to a return of ‘blockbuster’ product launches, market expansion and mitigation strategies for current economic uncertainties.